Prognostic stratification ability of the CPS+EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy
The CPS+EG scoring system was initially described in unselected early breast cancer (eBC) patients treated with neoadjuvant chemotherapy (NAC), leading to refined prognostic stratification, and thus helping to select patients for additional post-NAC treatments. It remains unknown whether the perform...
Gespeichert in:
| Veröffentlicht in: | European journal of cancer (1990) 2024-05, Vol.202, p.114037-114037, Article 114037 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 114037 |
|---|---|
| container_issue | |
| container_start_page | 114037 |
| container_title | European journal of cancer (1990) |
| container_volume | 202 |
| creator | Roussot, Nicolas Constantin, Guillaume Desmoulins, Isabelle Bergeron, Anthony Arnould, Laurent Beltjens, Françoise Mayeur, Didier Kaderbhai, Courèche Hennequin, Audrey Jankowski, Clémentine Padeano, Marie Martine Costaz, Hélène Jacinto, Sarah Michel, Eloise Amet, Alix Coutant, Charles Costa, Brigitte Jouannaud, Christelle Deblock, Mathilde Levy, Christelle Ferrero, Jean-Marc Kerbrat, Pierre Brain, Etienne Mouret-Reynier, Marie-Ange Coudert, Bruno Bertaut, Aurélie Ladoire, Sylvain |
| description | The CPS+EG scoring system was initially described in unselected early breast cancer (eBC) patients treated with neoadjuvant chemotherapy (NAC), leading to refined prognostic stratification, and thus helping to select patients for additional post-NAC treatments. It remains unknown whether the performance is the same in new biological breast cancer entities such as the HER2-low subtype.
Outcomes (disease-free (DFS) and overall survival OS)) of 608 patients with HER2-non amplified eBC and treated with NAC were retrospectively analyzed according to CPS-EG score. We compared the prognostic stratification abilities of the CPS+EG in HER2-low and HER2–0 eBC, analyzing ER+ and ER- tumors separately.
In ER+ eBC, the CPS+EG scoring system seems to retain a prognostic value, both in HER2-low and HER2–0 tumors, by distinguishing populations with significantly different outcomes (good: score 0–1, poor: score 2–3, and very poor: score 4–5). Using C-indices for DFS and OS, CPS+EG provided the highest prognostic information in ER+ eBC, especially in HER2–0 tumors. In contrast, in ER- eBC, the CPS+EG does not appear to be able to distinguish different outcome groups, either in HER2-low or HER2–0 tumors. In ER- eBC, C-indices for DFS and OS were highest for pathological stage, reflecting the predominant prognostic importance of residual disease in this subtype.
HER2-low status does not influence the prognostic performance of the CPS+EG score. Our results confirm the usefulness of the CPS+EG score in stratifying the prognosis of ER+ eBC after NAC, for both HER2–0 and HER2-low tumors. For ER- eBC, HER2-low status does not influence the performance of the CPS+EG score, which was lower than that of the pathological stage alone.
•HER2-low status does not influence the prognostic performance of the CPS+EG score.•For ER+ eBC, the CPS+EG score properly stratifies both HER2-0 and HER2-low tumors.•For ER- eBC, the performance of the CPS+EG score is lower than that of the PS alone. |
| doi_str_mv | 10.1016/j.ejca.2024.114037 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_04662176v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0959804924006932</els_id><sourcerecordid>3022576971</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3007-8ca04e2d94a3e2e0c4b345904f006e80d2089c8622f931a89118720f68835ec3</originalsourceid><addsrcrecordid>eNp9kcFu1DAQhiMEotvCC3BAPlJVWcaOk9gSl2q1dJFWooLeLa8z6TrKxovt3So8Bk-Mo5Qeudga-5t_NP-fZR8oLCnQ6nO3xM7oJQPGl5RyKOpX2YKKWuYgSvY6W4AsZS6Ay4vsMoQOAGrB4W12UYiy5CVni-zPvXePgwvRGhKi19G21qTTDUTvbG_jSFxL4h7J6v7nzfqOBOO8HR5JGEPEA7ED2ax_sLx3T0QPzVz8Ru8Iat-PZOdRh0iMHgx6ElMVsSFPNu7JgE433emsh_S_x4NLU7w-ju-yN63uA75_vq-yh6_rh9Um336_-7a63eamSIvkwmjgyBrJdYEMwfBdwUsJvAWoUEDDQEgjKsZaWVAtJE3WMGgrIYoSTXGVXc-ye92ro7cH7UfltFWb262a3oBXFaN1daaJ_TSzR-9-nTBEdbDBYN_rtMQpqAIYK-tK1hPKZtR4F4LH9kWbgppiU52aYlNTbGqOLTV9fNY_7Q7YvLT8yykBX2YAkyFni14FYzF52liPJqrG2f_p_wVIIqf0</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3022576971</pqid></control><display><type>article</type><title>Prognostic stratification ability of the CPS+EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Roussot, Nicolas ; Constantin, Guillaume ; Desmoulins, Isabelle ; Bergeron, Anthony ; Arnould, Laurent ; Beltjens, Françoise ; Mayeur, Didier ; Kaderbhai, Courèche ; Hennequin, Audrey ; Jankowski, Clémentine ; Padeano, Marie Martine ; Costaz, Hélène ; Jacinto, Sarah ; Michel, Eloise ; Amet, Alix ; Coutant, Charles ; Costa, Brigitte ; Jouannaud, Christelle ; Deblock, Mathilde ; Levy, Christelle ; Ferrero, Jean-Marc ; Kerbrat, Pierre ; Brain, Etienne ; Mouret-Reynier, Marie-Ange ; Coudert, Bruno ; Bertaut, Aurélie ; Ladoire, Sylvain</creator><creatorcontrib>Roussot, Nicolas ; Constantin, Guillaume ; Desmoulins, Isabelle ; Bergeron, Anthony ; Arnould, Laurent ; Beltjens, Françoise ; Mayeur, Didier ; Kaderbhai, Courèche ; Hennequin, Audrey ; Jankowski, Clémentine ; Padeano, Marie Martine ; Costaz, Hélène ; Jacinto, Sarah ; Michel, Eloise ; Amet, Alix ; Coutant, Charles ; Costa, Brigitte ; Jouannaud, Christelle ; Deblock, Mathilde ; Levy, Christelle ; Ferrero, Jean-Marc ; Kerbrat, Pierre ; Brain, Etienne ; Mouret-Reynier, Marie-Ange ; Coudert, Bruno ; Bertaut, Aurélie ; Ladoire, Sylvain</creatorcontrib><description>The CPS+EG scoring system was initially described in unselected early breast cancer (eBC) patients treated with neoadjuvant chemotherapy (NAC), leading to refined prognostic stratification, and thus helping to select patients for additional post-NAC treatments. It remains unknown whether the performance is the same in new biological breast cancer entities such as the HER2-low subtype.
Outcomes (disease-free (DFS) and overall survival OS)) of 608 patients with HER2-non amplified eBC and treated with NAC were retrospectively analyzed according to CPS-EG score. We compared the prognostic stratification abilities of the CPS+EG in HER2-low and HER2–0 eBC, analyzing ER+ and ER- tumors separately.
In ER+ eBC, the CPS+EG scoring system seems to retain a prognostic value, both in HER2-low and HER2–0 tumors, by distinguishing populations with significantly different outcomes (good: score 0–1, poor: score 2–3, and very poor: score 4–5). Using C-indices for DFS and OS, CPS+EG provided the highest prognostic information in ER+ eBC, especially in HER2–0 tumors. In contrast, in ER- eBC, the CPS+EG does not appear to be able to distinguish different outcome groups, either in HER2-low or HER2–0 tumors. In ER- eBC, C-indices for DFS and OS were highest for pathological stage, reflecting the predominant prognostic importance of residual disease in this subtype.
HER2-low status does not influence the prognostic performance of the CPS+EG score. Our results confirm the usefulness of the CPS+EG score in stratifying the prognosis of ER+ eBC after NAC, for both HER2–0 and HER2-low tumors. For ER- eBC, HER2-low status does not influence the performance of the CPS+EG score, which was lower than that of the pathological stage alone.
•HER2-low status does not influence the prognostic performance of the CPS+EG score.•For ER+ eBC, the CPS+EG score properly stratifies both HER2-0 and HER2-low tumors.•For ER- eBC, the performance of the CPS+EG score is lower than that of the PS alone.</description><identifier>ISSN: 0959-8049</identifier><identifier>EISSN: 1879-0852</identifier><identifier>DOI: 10.1016/j.ejca.2024.114037</identifier><identifier>PMID: 38554542</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Breast cancer ; Breast Neoplasms - pathology ; Chemotherapy, Adjuvant ; CPS+EG ; Disease-Free Survival ; Female ; HER2 low ; HER2 zero ; Humans ; Life Sciences ; Neoadjuvant chemotherapy ; Neoadjuvant Therapy - methods ; Neoplasm Staging ; Prognosis ; Prognostic ; Receptor, ErbB-2 ; Retrospective Studies ; Stratification ; Survival</subject><ispartof>European journal of cancer (1990), 2024-05, Vol.202, p.114037-114037, Article 114037</ispartof><rights>2024 The Authors</rights><rights>Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3007-8ca04e2d94a3e2e0c4b345904f006e80d2089c8622f931a89118720f68835ec3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0959804924006932$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38554542$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-04662176$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Roussot, Nicolas</creatorcontrib><creatorcontrib>Constantin, Guillaume</creatorcontrib><creatorcontrib>Desmoulins, Isabelle</creatorcontrib><creatorcontrib>Bergeron, Anthony</creatorcontrib><creatorcontrib>Arnould, Laurent</creatorcontrib><creatorcontrib>Beltjens, Françoise</creatorcontrib><creatorcontrib>Mayeur, Didier</creatorcontrib><creatorcontrib>Kaderbhai, Courèche</creatorcontrib><creatorcontrib>Hennequin, Audrey</creatorcontrib><creatorcontrib>Jankowski, Clémentine</creatorcontrib><creatorcontrib>Padeano, Marie Martine</creatorcontrib><creatorcontrib>Costaz, Hélène</creatorcontrib><creatorcontrib>Jacinto, Sarah</creatorcontrib><creatorcontrib>Michel, Eloise</creatorcontrib><creatorcontrib>Amet, Alix</creatorcontrib><creatorcontrib>Coutant, Charles</creatorcontrib><creatorcontrib>Costa, Brigitte</creatorcontrib><creatorcontrib>Jouannaud, Christelle</creatorcontrib><creatorcontrib>Deblock, Mathilde</creatorcontrib><creatorcontrib>Levy, Christelle</creatorcontrib><creatorcontrib>Ferrero, Jean-Marc</creatorcontrib><creatorcontrib>Kerbrat, Pierre</creatorcontrib><creatorcontrib>Brain, Etienne</creatorcontrib><creatorcontrib>Mouret-Reynier, Marie-Ange</creatorcontrib><creatorcontrib>Coudert, Bruno</creatorcontrib><creatorcontrib>Bertaut, Aurélie</creatorcontrib><creatorcontrib>Ladoire, Sylvain</creatorcontrib><title>Prognostic stratification ability of the CPS+EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy</title><title>European journal of cancer (1990)</title><addtitle>Eur J Cancer</addtitle><description>The CPS+EG scoring system was initially described in unselected early breast cancer (eBC) patients treated with neoadjuvant chemotherapy (NAC), leading to refined prognostic stratification, and thus helping to select patients for additional post-NAC treatments. It remains unknown whether the performance is the same in new biological breast cancer entities such as the HER2-low subtype.
Outcomes (disease-free (DFS) and overall survival OS)) of 608 patients with HER2-non amplified eBC and treated with NAC were retrospectively analyzed according to CPS-EG score. We compared the prognostic stratification abilities of the CPS+EG in HER2-low and HER2–0 eBC, analyzing ER+ and ER- tumors separately.
In ER+ eBC, the CPS+EG scoring system seems to retain a prognostic value, both in HER2-low and HER2–0 tumors, by distinguishing populations with significantly different outcomes (good: score 0–1, poor: score 2–3, and very poor: score 4–5). Using C-indices for DFS and OS, CPS+EG provided the highest prognostic information in ER+ eBC, especially in HER2–0 tumors. In contrast, in ER- eBC, the CPS+EG does not appear to be able to distinguish different outcome groups, either in HER2-low or HER2–0 tumors. In ER- eBC, C-indices for DFS and OS were highest for pathological stage, reflecting the predominant prognostic importance of residual disease in this subtype.
HER2-low status does not influence the prognostic performance of the CPS+EG score. Our results confirm the usefulness of the CPS+EG score in stratifying the prognosis of ER+ eBC after NAC, for both HER2–0 and HER2-low tumors. For ER- eBC, HER2-low status does not influence the performance of the CPS+EG score, which was lower than that of the pathological stage alone.
•HER2-low status does not influence the prognostic performance of the CPS+EG score.•For ER+ eBC, the CPS+EG score properly stratifies both HER2-0 and HER2-low tumors.•For ER- eBC, the performance of the CPS+EG score is lower than that of the PS alone.</description><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - pathology</subject><subject>Chemotherapy, Adjuvant</subject><subject>CPS+EG</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>HER2 low</subject><subject>HER2 zero</subject><subject>Humans</subject><subject>Life Sciences</subject><subject>Neoadjuvant chemotherapy</subject><subject>Neoadjuvant Therapy - methods</subject><subject>Neoplasm Staging</subject><subject>Prognosis</subject><subject>Prognostic</subject><subject>Receptor, ErbB-2</subject><subject>Retrospective Studies</subject><subject>Stratification</subject><subject>Survival</subject><issn>0959-8049</issn><issn>1879-0852</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kcFu1DAQhiMEotvCC3BAPlJVWcaOk9gSl2q1dJFWooLeLa8z6TrKxovt3So8Bk-Mo5Qeudga-5t_NP-fZR8oLCnQ6nO3xM7oJQPGl5RyKOpX2YKKWuYgSvY6W4AsZS6Ay4vsMoQOAGrB4W12UYiy5CVni-zPvXePgwvRGhKi19G21qTTDUTvbG_jSFxL4h7J6v7nzfqOBOO8HR5JGEPEA7ED2ax_sLx3T0QPzVz8Ru8Iat-PZOdRh0iMHgx6ElMVsSFPNu7JgE433emsh_S_x4NLU7w-ju-yN63uA75_vq-yh6_rh9Um336_-7a63eamSIvkwmjgyBrJdYEMwfBdwUsJvAWoUEDDQEgjKsZaWVAtJE3WMGgrIYoSTXGVXc-ye92ro7cH7UfltFWb262a3oBXFaN1daaJ_TSzR-9-nTBEdbDBYN_rtMQpqAIYK-tK1hPKZtR4F4LH9kWbgppiU52aYlNTbGqOLTV9fNY_7Q7YvLT8yykBX2YAkyFni14FYzF52liPJqrG2f_p_wVIIqf0</recordid><startdate>202405</startdate><enddate>202405</enddate><creator>Roussot, Nicolas</creator><creator>Constantin, Guillaume</creator><creator>Desmoulins, Isabelle</creator><creator>Bergeron, Anthony</creator><creator>Arnould, Laurent</creator><creator>Beltjens, Françoise</creator><creator>Mayeur, Didier</creator><creator>Kaderbhai, Courèche</creator><creator>Hennequin, Audrey</creator><creator>Jankowski, Clémentine</creator><creator>Padeano, Marie Martine</creator><creator>Costaz, Hélène</creator><creator>Jacinto, Sarah</creator><creator>Michel, Eloise</creator><creator>Amet, Alix</creator><creator>Coutant, Charles</creator><creator>Costa, Brigitte</creator><creator>Jouannaud, Christelle</creator><creator>Deblock, Mathilde</creator><creator>Levy, Christelle</creator><creator>Ferrero, Jean-Marc</creator><creator>Kerbrat, Pierre</creator><creator>Brain, Etienne</creator><creator>Mouret-Reynier, Marie-Ange</creator><creator>Coudert, Bruno</creator><creator>Bertaut, Aurélie</creator><creator>Ladoire, Sylvain</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope></search><sort><creationdate>202405</creationdate><title>Prognostic stratification ability of the CPS+EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy</title><author>Roussot, Nicolas ; Constantin, Guillaume ; Desmoulins, Isabelle ; Bergeron, Anthony ; Arnould, Laurent ; Beltjens, Françoise ; Mayeur, Didier ; Kaderbhai, Courèche ; Hennequin, Audrey ; Jankowski, Clémentine ; Padeano, Marie Martine ; Costaz, Hélène ; Jacinto, Sarah ; Michel, Eloise ; Amet, Alix ; Coutant, Charles ; Costa, Brigitte ; Jouannaud, Christelle ; Deblock, Mathilde ; Levy, Christelle ; Ferrero, Jean-Marc ; Kerbrat, Pierre ; Brain, Etienne ; Mouret-Reynier, Marie-Ange ; Coudert, Bruno ; Bertaut, Aurélie ; Ladoire, Sylvain</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3007-8ca04e2d94a3e2e0c4b345904f006e80d2089c8622f931a89118720f68835ec3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - pathology</topic><topic>Chemotherapy, Adjuvant</topic><topic>CPS+EG</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>HER2 low</topic><topic>HER2 zero</topic><topic>Humans</topic><topic>Life Sciences</topic><topic>Neoadjuvant chemotherapy</topic><topic>Neoadjuvant Therapy - methods</topic><topic>Neoplasm Staging</topic><topic>Prognosis</topic><topic>Prognostic</topic><topic>Receptor, ErbB-2</topic><topic>Retrospective Studies</topic><topic>Stratification</topic><topic>Survival</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Roussot, Nicolas</creatorcontrib><creatorcontrib>Constantin, Guillaume</creatorcontrib><creatorcontrib>Desmoulins, Isabelle</creatorcontrib><creatorcontrib>Bergeron, Anthony</creatorcontrib><creatorcontrib>Arnould, Laurent</creatorcontrib><creatorcontrib>Beltjens, Françoise</creatorcontrib><creatorcontrib>Mayeur, Didier</creatorcontrib><creatorcontrib>Kaderbhai, Courèche</creatorcontrib><creatorcontrib>Hennequin, Audrey</creatorcontrib><creatorcontrib>Jankowski, Clémentine</creatorcontrib><creatorcontrib>Padeano, Marie Martine</creatorcontrib><creatorcontrib>Costaz, Hélène</creatorcontrib><creatorcontrib>Jacinto, Sarah</creatorcontrib><creatorcontrib>Michel, Eloise</creatorcontrib><creatorcontrib>Amet, Alix</creatorcontrib><creatorcontrib>Coutant, Charles</creatorcontrib><creatorcontrib>Costa, Brigitte</creatorcontrib><creatorcontrib>Jouannaud, Christelle</creatorcontrib><creatorcontrib>Deblock, Mathilde</creatorcontrib><creatorcontrib>Levy, Christelle</creatorcontrib><creatorcontrib>Ferrero, Jean-Marc</creatorcontrib><creatorcontrib>Kerbrat, Pierre</creatorcontrib><creatorcontrib>Brain, Etienne</creatorcontrib><creatorcontrib>Mouret-Reynier, Marie-Ange</creatorcontrib><creatorcontrib>Coudert, Bruno</creatorcontrib><creatorcontrib>Bertaut, Aurélie</creatorcontrib><creatorcontrib>Ladoire, Sylvain</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>European journal of cancer (1990)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Roussot, Nicolas</au><au>Constantin, Guillaume</au><au>Desmoulins, Isabelle</au><au>Bergeron, Anthony</au><au>Arnould, Laurent</au><au>Beltjens, Françoise</au><au>Mayeur, Didier</au><au>Kaderbhai, Courèche</au><au>Hennequin, Audrey</au><au>Jankowski, Clémentine</au><au>Padeano, Marie Martine</au><au>Costaz, Hélène</au><au>Jacinto, Sarah</au><au>Michel, Eloise</au><au>Amet, Alix</au><au>Coutant, Charles</au><au>Costa, Brigitte</au><au>Jouannaud, Christelle</au><au>Deblock, Mathilde</au><au>Levy, Christelle</au><au>Ferrero, Jean-Marc</au><au>Kerbrat, Pierre</au><au>Brain, Etienne</au><au>Mouret-Reynier, Marie-Ange</au><au>Coudert, Bruno</au><au>Bertaut, Aurélie</au><au>Ladoire, Sylvain</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic stratification ability of the CPS+EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy</atitle><jtitle>European journal of cancer (1990)</jtitle><addtitle>Eur J Cancer</addtitle><date>2024-05</date><risdate>2024</risdate><volume>202</volume><spage>114037</spage><epage>114037</epage><pages>114037-114037</pages><artnum>114037</artnum><issn>0959-8049</issn><eissn>1879-0852</eissn><abstract>The CPS+EG scoring system was initially described in unselected early breast cancer (eBC) patients treated with neoadjuvant chemotherapy (NAC), leading to refined prognostic stratification, and thus helping to select patients for additional post-NAC treatments. It remains unknown whether the performance is the same in new biological breast cancer entities such as the HER2-low subtype.
Outcomes (disease-free (DFS) and overall survival OS)) of 608 patients with HER2-non amplified eBC and treated with NAC were retrospectively analyzed according to CPS-EG score. We compared the prognostic stratification abilities of the CPS+EG in HER2-low and HER2–0 eBC, analyzing ER+ and ER- tumors separately.
In ER+ eBC, the CPS+EG scoring system seems to retain a prognostic value, both in HER2-low and HER2–0 tumors, by distinguishing populations with significantly different outcomes (good: score 0–1, poor: score 2–3, and very poor: score 4–5). Using C-indices for DFS and OS, CPS+EG provided the highest prognostic information in ER+ eBC, especially in HER2–0 tumors. In contrast, in ER- eBC, the CPS+EG does not appear to be able to distinguish different outcome groups, either in HER2-low or HER2–0 tumors. In ER- eBC, C-indices for DFS and OS were highest for pathological stage, reflecting the predominant prognostic importance of residual disease in this subtype.
HER2-low status does not influence the prognostic performance of the CPS+EG score. Our results confirm the usefulness of the CPS+EG score in stratifying the prognosis of ER+ eBC after NAC, for both HER2–0 and HER2-low tumors. For ER- eBC, HER2-low status does not influence the performance of the CPS+EG score, which was lower than that of the pathological stage alone.
•HER2-low status does not influence the prognostic performance of the CPS+EG score.•For ER+ eBC, the CPS+EG score properly stratifies both HER2-0 and HER2-low tumors.•For ER- eBC, the performance of the CPS+EG score is lower than that of the PS alone.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>38554542</pmid><doi>10.1016/j.ejca.2024.114037</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0959-8049 |
| ispartof | European journal of cancer (1990), 2024-05, Vol.202, p.114037-114037, Article 114037 |
| issn | 0959-8049 1879-0852 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_04662176v1 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use Breast cancer Breast Neoplasms - pathology Chemotherapy, Adjuvant CPS+EG Disease-Free Survival Female HER2 low HER2 zero Humans Life Sciences Neoadjuvant chemotherapy Neoadjuvant Therapy - methods Neoplasm Staging Prognosis Prognostic Receptor, ErbB-2 Retrospective Studies Stratification Survival |
| title | Prognostic stratification ability of the CPS+EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T14%3A04%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20stratification%20ability%20of%20the%20CPS+EG%20scoring%20system%20in%20HER2-low%20and%20HER2-zero%20early%20breast%20cancer%20treated%20with%20neoadjuvant%20chemotherapy&rft.jtitle=European%20journal%20of%20cancer%20(1990)&rft.au=Roussot,%20Nicolas&rft.date=2024-05&rft.volume=202&rft.spage=114037&rft.epage=114037&rft.pages=114037-114037&rft.artnum=114037&rft.issn=0959-8049&rft.eissn=1879-0852&rft_id=info:doi/10.1016/j.ejca.2024.114037&rft_dat=%3Cproquest_hal_p%3E3022576971%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3022576971&rft_id=info:pmid/38554542&rft_els_id=S0959804924006932&rfr_iscdi=true |